About Investors Technology Products News Contact News, etc. LATEST PRESS RELEASES March 04, 2021 Product and Regulatory Update on MedMira’s COVID-19 Product Family Halifax, Nova Scotia, 03 March, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its product portfolio and outlines the company’s COVID-19 market and regulatory plan. January 29, 2021 Progress Update on MedMira’s COVID-19 Product Family Halifax, Nova Scotia, 29 January, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of the neutralizing antibodies against the SARS-CoV-2 virus. These antibodies bind to the specific parts of the virus, decreasing the viral infectivity and potentially protecting the patient from the severe COVID-19 symptom presentation or future SARS-CoV-2 reinfection. Not all antibodies can block the virus from infecting the patient, and, according to the recent reports, the levels of neutralizing antibodies vary, so as the potency of the antibody protection. December 31, 2020 MedMira Announces Product Update Halifax, Nova Scotia, 30 December, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR), is pleased to announce its validated REVEALCOVID-19™ PLUS Total Antibody Test for the detection of total antibodies against both the Nucleocapsid and Spike regions of the SARS-CoV-2. REVEALCOVID-19™ PLUS Total Antibody Test is an update to MedMira’s REVEALCOVID-19™ Total Antibody Test that addresses the total antibody testing demands arising from recent developments in COVID-19 vaccines across global markets. December 24, 2020 MedMira Reports First Quarter Results FY2021 Halifax, Nova Scotia, December 24, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2020. December 1, 2020 MedMira Reports FY2020 Fourth Quarter and Year End Financial Results Halifax, Nova Scotia, November 30, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results forthe financial year ended July 31, 2019. June 30, 2020 Management’s Discussion & Analysis For the nine months ended April 30, 2020 This document contains forward looking statements, such as statements regarding future sales opportunities in various global regions and financing initiatives that are based on current expectations of management. These statements involve uncertainties and risks, including MedMira Inc.’s (“MedMira” or the “Company”) ability to obtain and/or access additional financing with acceptable terms, and delays in anticipated product sales. June 30, 2020 Condensed Interim Consolidated Financial Statements For the nine months ended April 30, 2020 and April 30, 2019 (Unaudited – Prepared by Management) In accordance with National Instrument 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the unaudited financial statements for the period ending April 30, 2020 June 29, 2020 MedMira Reports Third Quarter Results FY2020 Halifax, Nova Scotia, June 29, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2020. May 27, 2020 MedMira Announces Exclusive Distribution Partnership with Webb Diagnostic Technologies and Initial Order for REVEALCOVID-19™ Total Antibody Test in the U.S. Halifax, Nova Scotia, 27 May, 2020 – MedMira Inc. (MedMira) (TSXV: MIR) announces that company has entered into an Exclusive Distribution Agreement with Webb Diagnostic Technologies, Inc., (WebbDX) for the distribution of MedMira’s REVEALCOVID-19™ Total Antibody Test. Webb Diagnostic Technologies has placed the first order with the purchase value of approximately CDN$3.5 million. The Company has received the down payment to initiate the production process. May 21, 2020 MedMira Announces Progress Update of its REVEALCOVID-19TM Total Antibody test including CE mark Halifax, Nova Scotia, 21. May, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that it has completed the registration process and affixed the CE mark (Conformité Européene) to its rapid REVEALCOVID- 19TM Total Antibody Test. April 23, 2020 MedMira Announces Notification Submission to US FDA Emergency Use Authorization MedMira Inc. announced today that it had submitted the notification for the Emergency Use Authorization application offered by the U.S. Food and Drug Administration (FDA) for its newest member of its Reveal line of products for antibody testing. April 15, 2020 MedMira Announces Development of COVID-19 Point-of-Care Antibody Test MedMira Announces Update on Development of Point-of-Care Antibody Test MAR 31, 2020 MedMira Reports Second Quarter Results MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended March 31, 2020. DEC 30, 2019 MedMira Reports First Quarter Results MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2019. NOV 28, 2019 MedMira Reports 2019 Fourth Quarter and Year End Financial Results MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the financial year ended July 31, 2019. JUN 29, 2019 MedMira Reports Third Quarter Results MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2019 MAR 29, 2019 MedMira Reports Second Quarter Results MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended January 31, 2019. MAR 28, 2019 Medmira Reports 2018 Fourth Quarter and Year End Financial Results MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the financial year ended July 31, 2018. MAR 14, 2019 Management Cease Trade Order Update MedMira Inc. (TSXV: MIR) (“MedMira” or the “Company”) provides an update with respect to the previously announced management cease trade order (the “MCTO”) issued by the Nova Scotia Securities Commission on November 29, 2018. FEB 5, 2019 Management Cease Trade Order Update MedMira Inc. (TSXV: MIR) (“MedMira” or the “Company”) provides an update with respect to the previously announced management cease trade order (the “MCTO”) issued by the Nova Scotia Securities Commission on November 29, 2018. JAN 22, 2019 Management Cease Trade Order Update MedMira Inc. (TSXV: MIR) (“MedMira” or the “Company”) provides an update with respect to the previously announced management cease trade order (the “MCTO”) issued by the Nova Scotia Securities Commission on November 29, 2018. JAN 8, 2019 Management Cease Trade Order Update MedMira Inc. (TSXV: MIR) (“MedMira” or the “Company”) provides an update with respect to the previously announced management cease trade order (the “MCTO”) issued by the Nova Scotia Securities Commission on November 29, 2018. DEC 28, 2018 Medmira Reports First Quarter Results MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2018. DEC 25, 2018 Management Cease Trade Order Update MedMira Inc. (TSXV: MIR) (“MedMira” or the “Company”) provides an update with respect to the previously announced management cease trade order (the “MCTO”) issued by the Nova Scotia Securities Commission on November 29, 2018. DEC 11, 2018 Management Cease Trade Order Update MedMira Inc. (TSXV: MIR) (“MedMira” or the “Company”) provides an update with respect to the previously announced management cease trade order (the “MCTO”) issued by the Nova Scotia Securities Commission on November 29, 2018. NOV 27, 2018 MedMira Inc. Announces Appointment of Auditor and Late Filing of Annual Financial Statements MedMira Inc. (MedMira) (TSXV: MIR), announced today that it has engaged Arsenault Best Cameron Ellis of Charlottetown, Prince Edward Island, as auditor for the Company’s financial statements for the year ended July 31, 2018. SEPT 6, 2018 MedMira Announces Revocation of Cease Trade Order MedMira Inc. (MedMira) (TSXV: MIR), announced that the Nova Scotia Securities Commission has revoked the Cease Trade Order. JUNE 29, 2018 MedMira Reports Third Quarter Results MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2018. MARCH 29, 2018 MedMira Reports Second Quarter Results MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended January 31, 2018. FEBRUARY 1, 2018 MedMira Announces AGM Results and Stock Option Grant MedMira Inc. (MedMira) (TSXV: MIR) held its 2018 Annual General Meeting of Shareholders on January 31, 2018 in Halifax, Nova Scotia. DECEMBER 22, 2017 MedMira Reports First Quarter Results MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2017. NOVEMBER 28, 2017 MedMira Reports 2017 Fourth Quarter and Year End Financial Results MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter and year ended July 31, 2017. JUNE 29, 2017 MedMira Reports FY2017 Third Quarter Results MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the three and nine month periods ending April 30, 2017. MAY 1, 2017 MedMira Receives CE Mark for Syphilis/HIV Multipex Rapid Test MedMira Inc. (MedMira) (TSXV:MIR), has received CE Mark on its syphilis/HIV rapid test, Multiplo TP/HIV. MARCH 31, 2017 MedMira Reports FY2017 Second Quarter Results MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the three and six month periods ending January 31, 2017. JANUARY 30, 2017 MedMira Announces AGM Results and Stock Option Grant MedMira Inc. (MedMira) (TSXV:MIR), held its Annual General Meeting of Shareholders on January 27, 2017. MORE NEWS RELEASES CONTACT US | LEGAL INFO | NEWS & EVENTS ©2020 MedMira Inc. All Rights Reserved. Follow us on